January 11, 2019
NanoCarrier said on January 9 that it has submitted a clinical trial authorization (CTA) for a global PII study of its investigational cancer agent NC-6004 in combination with the anti-PD-1 antibody Keytruda (pembrolizumab) for the treatment of head and neck...read more